Crossmark

Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1007/s00277-018-3366-x

Published Online: 2018-05-25

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Carella, A. M.

Corradini, P.

Mussetti, A.

Ricardi, U.

Vitolo, U.

Viviani, S.
License Information

Text and Data Mining valid from 2018-05-25
More Information

Article History

Received: 11 February 2018

Accepted: 6 May 2018

First Online: 25 May 2018

Compliance with ethical standards

:

: Carella AM: No conflict of interest; Corradini P.: Speaker Honoraria: Novartis, Celgene, Janssen, Gilead; Mussetti A.: no conflict of interest; Ricardi U.: no conflict of interest; Vitolo U.: Roche, Celgene, Janssen, Gilead, Takeda; Viviani S.: Takeda International: Consultancy, Research funding; Takeda Italia SpA: Speakers bureau, Travel and Accommodation expenses; Italfarmaco Consultancy.